drugset / Trial / NCT06998628
Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Phase 2
Recruiting
50 enrolled
Tanta University
Dr. Mustafa Adel Mustafa Elmenawy Lecturer of Rheumatology and Rehabilitation, Faculty of Medicine - El-Azhar University - Damietta · collabProf. Sahar Kamal Hegazy, Professor of Clinical Pharmacy, Faculty of Pharmacy - Tanta University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Timeline
- Start
- 2025-06-02
- Primary completion
- 2026-05-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pentoxifylline | Small molecule | 400 mg | — |
| Comparator | Methotrexate | Small molecule | — | — |